⁹⁰Yttrium–ibritumomab tiuxetan: a novel treatment for non-Hodgkin’s lymphoma

Bibliography

• MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Ritwdmab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Clin. Once]. (1998) 16:2825–2833.
   PubMed Web of Science ®Google Scholar
• •Pivotal trial of rituximab in low-grade NHL.
   Google Scholar
• LEONARD JP, COLEMAN M, MATTHEW JC et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma. Blood (2002) 100:1388 (Abstract).
   Google Scholar
• GAETANO ND, XIAO Y, ERBA E et al: Synergism between fludarabine and rituximab revealed in follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Ham-late]. (2001) 114:800–809.
   PubMed Web of Science ®Google Scholar
• CHOW KU, SOMMERLAD WD, BOEHER S et al: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica (2002) 87:33–43.
   PubMed Web of Science ®Google Scholar
• CRAWFORD LM: New therapy for non-Hodgkin lymphoma. JAMA (2002) 287:1640.
   PubMed Web of Science ®Google Scholar
• GARBER K: Lymphoma market turf war imminent, pending Bexxar approval. Nat. Biutechnol. (2003) 21:115–116.
   PubMed Web of Science ®Google Scholar
• GARBER K: For Bexxar, FDA meeting offers long-awaited chance at approval. Natl. Cancer Inst. (2002) 94:1738–1739.
   Google Scholar
• MULTANI P: Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. Int. I Hematul. (2002) 76: 410–410.
   Google Scholar
• STASHENKO P, NADLER L, HARDY R et al.: Characterization of a human B lymphocyte-specific antigen. I brununol. (1980) 125:1678–1685.
   Google Scholar
• KNOX SJ, GORIS ML, TRISLER K et al.: Yttrium-90-labeled anti-CD20 monclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. (1996) 2:457–470.
   PubMed Web of Science ®Google Scholar
• ••First clinical trial using 93Y-labelled anti-CD20 antibodies.
   Google Scholar
• WITZIG TE, WHITE CE, WISEMAN G et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma.' Clin. Once]. (1999) 17:3793–3803.
   Google Scholar
• ••Preliminary efficacy study of90Y-ibritumomab tiuxetan in relapsed/refractory NHL.
   Google Scholar
• WISEMAN G, WHITE CA, STABIN M et al.: Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Euc I Nucl. Med. (2000) 27:766–777.
   PubMedGoogle Scholar
• WISEMAN G, KORNMEH E, LEIGH B et al.: Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J. Nucl. Med. (2003) 44:465–474.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, FLINN IW, GORDON LI et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. I Clin. Once]. (2002) 20:3262–3269.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, GORDON LI, CABANILLAS F et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. I Clin. Once]. (2002) 30:2453–2463.
   Web of Science ®Google Scholar
• ••Randomised Phase III trial of93Y-ibritumomab tiuxetan in relapsed/refractory NHL.
   Google Scholar
• WITZIG TE, GORDON LI, GASTON I et al.: 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy of follicular NHL: results by follicular subtype. Proc. Am. Soc. Clin. Oncol (2002) 21:1063 (Abstract).
   Google Scholar
• EMMANOUILIDES CE, SILVERMAN D, LEIGH B et al: Successful treatment of Waldenstrom's macroglobulinemia with Zevalin-based therapy: a case report. Blood (2001) 98:4691 (Abstract).
   Google Scholar
• WITZIG TE, GORDON LI, EMMANOUILIDES CE et al.: Safety and efficacy of Zevalin in four patients with mucosa associated lymphoid tissue (MALT) lymphoma. Blood (2001) 98:4746 (Abstract).
   Google Scholar
• BARTLETT NL, WITZIG TE, GORDON LI et al.: 90Y-ibritumomab titixetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol (2002) 21:51 (Abstract).
   Google Scholar
• GORDON LI, WITZIG TE, EMMANOUILIDES CE et al: 90Y-ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity. Proc. Am. Soc. Clin. Oncol (2002) 21:1061 (Abstract).
   Google Scholar
• YOUNES A, PRO B, DELPASSAND E et al.: A Phase II study of 90Yttrium-ibritumomab (Zevalin) for the treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood (2003) 102:1461 (Abstract).
   Google Scholar
• WITZIG TE, WHITE CA, GORDON LI et al.: Safety of yttrium-90 ibritumomab titixetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. .1. Clin. Oncol (2003) 21:1263-1270. Review of the toxicities encountered in five different clinical trials using 90Y—ibritumomab tiuxetan.
   Google Scholar
• ANSELL SM, RISTOW KM, HABERMANN TM et al.: Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab titixetan for non-Hodgkin's lymphoma. J. Clin. Oncol (2002) 20:3885–3890.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, WISEMAN GA, GEYER SM et al.: A phase I trial of two-sequential doses of Zevalin radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma. Blood (2003) 102:1475 (Abstract).
   Google Scholar
• EMMANOUILIDES C, MURRAY IL, VO K et al.: Earlier treatment with yttrium 90 ibritumomab titixetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma (NHL): results with second-line therapy. Blood (2003) 102:4949 (Abstract).
   Google Scholar
• VOSE JM, BIERMAN PJ, LYNCH IC et al.: Phase I clinical trial of Zevalin (90Y-ibritumomab) in patient with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT). Blood (2003) 102:92 (Abstract).
   Google Scholar
• COIFFIER B, LEPAGE E, BRIERE J et al:CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl. J. Med. (2002) 346:235–242.
   PubMed Web of Science ®Google Scholar
• WINTER JM, INWARDS D, ERWIN W et al.: Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell transplant in non-Hodgkin's lymphoma: early outcome results. Blood (2002) 100:1597 (Abstract).
   Google Scholar
• NADEMANEE A, MOLINA A, FORMAN S et al.: A Phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (AS CT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL). Blood (2002) 100:679 (Abstract).
   Google Scholar